Barclays PLC Entrada Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 45,110 shares of TRDA stock, worth $793,484. This represents 0.0% of its overall portfolio holdings.

Number of Shares

45,110

Previous 45,110 -0.0%

Holding current value

$793,484

Previous $720,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$13.65 - $17.86 $417,485 - $546,248	30,585 Added 210.57%	45,110 $720,000
Q2 2024 Aug 14, 2024	SELL	$11.85 - $16.45 $94,705 - $131,468	-7,992 Reduced 35.49%	14,525 $208,000
Q1 2024 May 15, 2024	SELL	$11.58 - $17.0 $106,686 - $156,621	-9,213 Reduced 29.04%	22,517 $318,000
Q4 2023 Feb 15, 2024	BUY	$11.36 - $16.99 $293,065 - $438,308	25,798 Added 434.9%	31,730 $479,000
Q3 2023 Nov 07, 2023	SELL	$13.61 - $18.01 $6,913 - $9,149	-508 Reduced 7.89%	5,932 $94,000
Q2 2023 Aug 03, 2023	SELL	$11.02 - $18.01 $41,743 - $68,221	-3,788 Reduced 37.04%	6,440 $97,000
Q1 2023 May 04, 2023	SELL	$9.58 - $16.2 $5,211 - $8,812	-544 Reduced 5.05%	10,228 $149,000
Q4 2022 Feb 13, 2023	BUY	$13.52 - $22.89 $129,210 - $218,759	9,557 Added 786.58%	10,772 $146,000
Q3 2022 Nov 03, 2022	BUY	$9.65 - $15.76 $11,377 - $18,581	1,179 Added 3275.0%	1,215 $19,000
Q2 2022 Aug 12, 2022	SELL	$5.49 - $12.94 $9,184 - $21,648	-1,673 Reduced 97.89%	36 $0
Q1 2022 May 16, 2022	BUY	$7.99 - $16.93 $13,654 - $28,933	1,709 New	1,709 $16,000

Others Institutions Holding TRDA

# of Institutions

101

Shares Held

28.1M

Call Options Held

34.5K

Put Options Held

16.4K

View Full List

About Entrada Therapeutics, Inc.

Ticker TRDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,368,500
Market Cap $552M
Description
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...

More about TRDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account